Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
about
sameAs
Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugsThe serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptorsMonoacylglycerol lipase - a target for drug development?X-ray Crystallographic Analysis of α-Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide HydrolaseFluoride-Mediated Capture of a Noncovalent Bound State of a Reversible Covalent Enzyme Inhibitor: X-ray Crystallographic Analysis of an Exceptionally Potent α-Ketoheterocycle Inhibitor of Fatty Acid Amide HydrolaseReversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting AnalgesicsRational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site ResiduesTreating the Developing versus Developed Brain: Translating Preclinical Mouse and Human StudiesPotential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of AnxietyExploiting modern cannabinoid pharmacology for therapeutic gain?Long-term consequences of perinatal fatty acid amino hydrolase inhibition.Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.Molecular mechanisms involved in the side effects of fatty acid amide hydrolase inhibitors: a structural phenomics approach to proteome-wide cellular off-target deconvolution and disease association.Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.Discovery libraries targeting the major enzyme classes: the serine hydrolases.Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell.Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolaseLasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain.α-Ketoheterocycle-based Inhibitors of Fatty Acid Amide Hydrolase (FAAH).Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic propertiesCannabinoid modulation of neuroinflammatory disorders.Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹C]MPPO) Based on α-Ketoheterocyclic Scaffold.Mustard vesicants alter expression of the endocannabinoid system in mouse skin.Targeting the Endocannabinoid System for Neuroprotection: A (19)F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA.Design, synthesis, and characterization of α-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolaseIn vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors.Genes, molecules and patients--emerging topics to guide clinical pain research.Polyunsaturated fatty acids and endocannabinoids in health and disease.Hyperglycemia induces apoptosis via CB1 activation through the decrease of FAAH 1 in retinal pigment epithelial cells.Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase.Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine.
P2860
Q21090833-07AB9D1A-4266-410B-8A78-DE068B7223C1Q24602845-913623FC-B9A0-4EE3-866B-2568FEA3CACAQ26998964-5AF2D9B0-0F94-44B2-AA1F-206E1A7E3DE5Q27658264-474A005C-928B-496E-BCA1-4A931759ADD0Q27667078-F6C6D224-88D9-41C5-B00A-F3D9623907D4Q27667312-08E5E8F9-32C4-4D5C-B07C-79AFEC7EF753Q27677344-C8187AC0-F957-43EA-906F-8F932C601940Q28081132-BEA5D84D-5F74-4ADE-BFCF-D5B4E9D93C40Q28547916-CBB98B71-33B4-49EA-A0DA-EA0C3577CF40Q28728904-9916D4E2-D336-45C3-81D4-077660A31E1CQ30417555-A26F49A0-CEE5-4E02-B991-EB66B04B7840Q33560467-73B0DD82-4A2B-4632-A43D-38E20B16EB6CQ33644120-09253B50-FFA0-4972-A805-18B039D51E21Q33917845-597D7A27-50FA-4BD3-AEA0-80C86655FE7AQ34023143-383D650A-E8D6-4D49-9164-D0191EE52172Q34027721-56299D32-7EA3-46C7-AF08-385975E37D20Q34029257-C31EBB73-EEEA-4421-ADE4-B9D943701FF0Q34036280-E9D4A01F-61B2-4B5B-839F-48C37BEA6959Q34191995-74596EFC-0AF5-43E3-AF7B-E5F64A80CB1DQ34359778-BF7E8CAC-260F-42EB-BF42-48D9EE08DCA9Q34399907-3400E98B-CBB9-4C30-A787-31B8EA65D3D0Q34452685-666B2B69-6A18-41E2-8CDD-66439CD7C05BQ34503405-5B89B7A5-1BC7-419F-8C6B-5C658D28E175Q35655078-31B97FE1-6950-4366-8194-34CF7CF29181Q35986269-B96D3A73-9F2E-4680-9BB8-9FEE6911D49EQ36003998-06849290-515F-4978-8D98-D82F1063595DQ36067324-61E02770-B34B-4D34-9061-E730AE85E0BAQ36254356-81EF516D-AB9C-4AA4-9FCD-CB1C9700A0A3Q36727793-B4E86380-715E-40C4-B5B2-9105C730743AQ36926261-E8C15CD2-23C0-4A7F-9B47-C0ADD00D64F3Q37099962-837E8206-5C14-4E88-BE3E-15C05A03AA2DQ37579319-0D72F733-2D82-40D5-B472-421A04B880BFQ37613654-E59B27C9-C849-4C64-8510-ED0AC8BAE9B2Q37637750-9838EE7C-820E-4D98-A038-C4F2B096791DQ38028659-5567FAD6-2150-4ED1-860B-5BFBB1D38470Q38090292-14D74C9B-C8FF-4E7E-9763-3978BCC94F18Q39421016-3EEF776A-1B90-429F-853F-A0122DFC3E78Q39569586-97A16AAF-723F-4A42-8035-A2A7A2A9446FQ39768988-FDBC5E0D-923D-4CA2-8A8E-54B5CB35DFF9Q41547699-C270CEB4-91F3-4EE8-A469-D7E35A63B098
P2860
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@ast
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@en
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@nl
type
label
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@ast
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@en
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@nl
prefLabel
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@ast
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@en
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@nl
P2860
P1476
Fatty acid amide hydrolase as ...... ment of pain and CNS disorders
@en
P2093
Douglas S Johnson
P2860
P304
P356
10.1517/17460440903018857
P407
P577
2009-07-01T00:00:00Z